• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Efficacy and Safety of triplet versus doublet regimens in patients with multiple myeloma: A systematic review and meta-analysis

by | Apr 6, 2025 | Publications

Curr Probl Cancer. 2025 Apr 3;56:101202. doi: 10.1016/j.currproblcancer.2025.101202. Online ahead of print. ABSTRACT BACKGROUND: The efficacy and safety of various therapies for multiple myeloma (MM) remain a subject of ongoing debate, with inconsistent findings. This...

Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes

by | Apr 5, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Understanding the Use of Bispecific Antibodies in Multiple Myeloma

by | Apr 4, 2025 | Uncategorized

Source: CureToday articles Bispecific antibodies target specific cells, offering effective treatment for relapsed/refractory multiple myeloma, with varying side effect profiles. Read More

Caveolin-1 May Be A Promising Therapeutic Target For Multiple Myeloma, Study Finds

by | Apr 4, 2025 | Myeloma News

Source: Pharmacy Times articles CAV-1 is a key protein in lipid rafts that helps control cellular processes such as growth, survival, and migration. Read More

Overcoming Challenges and Advancing CAR-T Therapy for Myeloma

by | Apr 4, 2025 | Uncategorized

Source: CureToday articles CAR-T therapy for myeloma faces challenges in early-line use due to accessibility, eligibility criteria and long wait times, despite strong efficacy in trials. Read More
« Older Entries
Next Entries »

Recent Content

  • Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes
  • (no title)
  • Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis
  • (no title)
  • Peroxiredoxins as novel indicators in multiple myeloma associated with ferroptosis and immune infiltration
  • (no title)
  • (no title)
  • (no title)
  • (no title)
  • (no title)
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT